Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Saved in:
| Title: | Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. |
|---|---|
| Authors: | Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Facon T; University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France., Hungria V; Clínica Médica São Germano, São Paulo, Brazil., Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada., Venner CP; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.; BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada., Braunstein M; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Pour L; University Hospital Brno, Brno, Czech Republic., Martí JM; Hospital Universitario Mútua de Terrassa, Terrassa, Spain., Basu S; Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK., Cohen YC; Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.; Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel., Matsumoto M; Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan., Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan., Hulin C; Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France., Grosicki S; Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland., Legiec W; Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland., Beksac M; Istinye University, Ankara Liv Hospital, Ankara, Turkey., Maiolino A; Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Takamatsu H; Department of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan., Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., Turgut M; Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Ahmadi T; Genmab US, Inc., Plainsboro, NJ, USA., Liu W; Johnson & Johnson, Shanghai, China., Wang J; Johnson & Johnson, Spring House, PA, USA., Chastain K; Johnson & Johnson, Raritan, NJ, USA., Vermeulen J; Johnson & Johnson, Leiden, The Netherlands., Krevvata M; Johnson & Johnson, Spring House, PA, USA., Lopez-Masi L; Johnson & Johnson, Raritan, NJ, USA., Carey J; Johnson & Johnson, Spring House, PA, USA., Rowe M; Johnson & Johnson, High Wycombe, UK., Carson R; Johnson & Johnson, Spring House, PA, USA., Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. |
| Source: | Nature medicine [Nat Med] 2025 Apr; Vol. 31 (4), pp. 1366. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
